Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH2-terminal kinases

DSpace/Manakin Repository

Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH2-terminal kinases

Citable link to this page

 

 
Title: Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH2-terminal kinases
Author: Choukroun, Gabriel; Hajjar, Roger; Fry, Stefanie; Del Monte, Federica; Haq, Syed; Guerrero, J. Luis; Picard, Michael Howard; Rosenzweig, Anthony; Force, Thomas

Note: Order does not necessarily reflect citation order of authors.

Citation: Choukroun, Gabriel, Roger Hajjar, Stefanie Fry, Federica del Monte, Syed Haq, J. Luis Guerrero, Michael Picard, Anthony Rosenzweig, and Thomas Force. 1999. “Regulation of Cardiac Hypertrophy in Vivo by the Stress-Activated Protein Kinases/c-Jun NH2-Terminal Kinases.” Journal of Clinical Investigation 104 (4) (August 15): 391–398. doi:10.1172/jci6350. http://dx.doi.org/10.1172/JCI6350.
Full Text & Related Files:
Abstract: Cardiac hypertrophy often presages the development of heart failure. Numerous cytosolic signaling pathways have been implicated in the hypertrophic response in cardiomyocytes in culture, but their roles in the hypertrophic response to physiologically relevant stimuli in vivo is unclear. We previously reported that adenovirus-mediated gene transfer of SEK-1(KR), a dominant inhibitory mutant of the immediate upstream activator of the stress-activated protein kinases (SAPKs), abrogates the hypertrophic response of neonatal rat cardiomyocytes to endothelin-1 in culture. We now report that gene transfer of SEK-1(KR) to the adult rat heart blocks SAPK activation by pressure overload, demonstrating that the activity of cytosolic signaling pathways can be inhibited by gene transfer of loss-of-function mutants in vivo. Furthermore, gene transfer of SEK-1(KR) inhibited pressure overload–induced cardiac hypertrophy, as determined by echocardiography and several postmortem measures including left ventricular (LV) wall thickness, the ratio of LV weight to body weight, cardiomyocyte diameter, and inhibition of atrial natriuretic factor expression. Our data suggest that the SAPKs are critical regulators of cardiac hypertrophy in vivo, and therefore may serve as novel drug targets in the treatment of hypertrophy and heart failure.
Published Version: doi:10.1172/JCI6350
Other Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC408523/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:29048919
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters